CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers

CXCR4 is a cell membrane receptor that is overexpressed in triple-negative breast cancers and implicated in growth and metastasis of this disease. Using electrohydrodynamic cojetting, we prepared multicompartmental drug delivery carriers for CXCR4 targeting. The particles are comprised of a novel po...

Full description

Saved in:
Bibliographic Details
Published in:Biomacromolecules 2015-08, Vol.16 (8), p.2412-2417
Main Authors: Misra, Asish C, Luker, Kathryn E, Durmaz, Hakan, Luker, Gary D, Lahann, Joerg
Format: Article
Language:English
Subjects:
Benzylamines
Cell Line, Tumor
Cyclams
Drug Delivery Systems
Female
Heterocyclic Compounds - administration & dosage
Heterocyclic Compounds - chemistry
Humans
Nanoparticles - administration & dosage
Receptors, CXCR4 - antagonists & inhibitors
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CXCR4 is a cell membrane receptor that is overexpressed in triple-negative breast cancers and implicated in growth and metastasis of this disease. Using electrohydrodynamic cojetting, we prepared multicompartmental drug delivery carriers for CXCR4 targeting. The particles are comprised of a novel poly­(lactide-co-glycolide) derivative that allows for straightforward immobilization of 1,1′-[1,4-phenylenebis­(methylene)]­bis­[1,4,8,11-tetraazacyclotetradecane] (Plerixafor), a small molecule with affinity for CXCR4. Targeted nanocarriers are selectively taken up by CXCR4-expressing cells and effectively block CXCR4 signaling. This study suggests that CXCR4 may be an effective target for nanocarrier-based therapies.
ISSN:1525-7797
1526-4602
DOI:10.1021/acs.biomac.5b00653